Literature DB >> 19841163

IDO mediates TLR9-driven protection from experimental autoimmune diabetes.

Francesca Fallarino1, Claudia Volpi, Teresa Zelante, Carmine Vacca, Mario Calvitti, Maria C Fioretti, Paolo Puccetti, Luigina Romani, Ursula Grohmann.   

Abstract

Originally predicated on the recognition of an increasing prevalence of allergy, the hygiene hypothesis was later found to accommodate the contrasting epidemiologic trends in developed countries for infectious vs autoimmune diseases. Experimentally, reduced exposure to infections will increase the risk of disease in several models of experimental autoimmunity. Although TLRs were initially considered as stimulatory molecules capable of activating early defense mechanisms against invading pathogens, emerging data suggest that they can also exert a regulatory function. In the present study, we evaluated whether TLR3 and TLR9, recognizing microbial dsDNA and CpG-containing DNA sequences, respectively, play a role in the protection from experimental autoimmune diabetes induced in C57BL/6 mice by streptozotocin. In wild-type animals, the disease was accompanied by up-regulation of IDO in pancreatic lymph nodes and would be greatly exacerbated by in vivo administration of an IDO inhibitor. Conversely, administration of a CpG-containing oligodeoxynucleotide greatly attenuated the disease in an IDO-dependent fashion. TLR9-, but not TLR3-deficient mice developed a more robust disease, an event accompanied by lack of IDO induction in pancreatic lymph nodes. Thus, our data suggest that the TLR9-IDO axis may represent a valuable target in the prevention/therapy of type 1 diabetes.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19841163     DOI: 10.4049/jimmunol.0901577

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  50 in total

Review 1.  Historical overview of immunological tolerance.

Authors:  Ronald H Schwartz
Journal:  Cold Spring Harb Perspect Biol       Date:  2012-04-01       Impact factor: 10.005

Review 2.  Immune cell crosstalk in type 1 diabetes.

Authors:  Agnès Lehuen; Julien Diana; Paola Zaccone; Anne Cooke
Journal:  Nat Rev Immunol       Date:  2010-07       Impact factor: 53.106

Review 3.  Translating nucleic acid-sensing pathways into therapies.

Authors:  Tobias Junt; Winfried Barchet
Journal:  Nat Rev Immunol       Date:  2015-08-21       Impact factor: 53.106

4.  Aryl hydrocarbon receptor negatively regulates dendritic cell immunogenicity via a kynurenine-dependent mechanism.

Authors:  Nam Trung Nguyen; Akihiro Kimura; Taisuke Nakahama; Ichino Chinen; Kazuya Masuda; Keiko Nohara; Yoshiaki Fujii-Kuriyama; Tadamitsu Kishimoto
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-01       Impact factor: 11.205

5.  Simultaneous TLR2 inhibition and TLR9 activation synergistically suppress tumor metastasis in mice.

Authors:  Jun Yan; Fang Hua; Han-zhi Liu; Hong-zheng Yang; Zhuo-wei Hu
Journal:  Acta Pharmacol Sin       Date:  2012-03-19       Impact factor: 6.150

Review 6.  Chemo-Immunotherapy: Role of Indoleamine 2,3-Dioxygenase in Defining Immunogenic Versus Tolerogenic Cell Death in the Tumor Microenvironment.

Authors:  Theodore S Johnson; Tracy Mcgaha; David H Munn
Journal:  Adv Exp Med Biol       Date:  2017       Impact factor: 2.622

Review 7.  Targeting Type 1 Diabetes: Selective Approaches for New Therapies.

Authors:  Daniel F Sheehy; Sean P Quinnell; Arturo J Vegas
Journal:  Biochemistry       Date:  2019-01-17       Impact factor: 3.162

8.  High doses of CpG oligodeoxynucleotides stimulate a tolerogenic TLR9-TRIF pathway.

Authors:  Claudia Volpi; Francesca Fallarino; Maria T Pallotta; Roberta Bianchi; Carmine Vacca; Maria L Belladonna; Ciriana Orabona; Antonella De Luca; Louis Boon; Luigina Romani; Ursula Grohmann; Paolo Puccetti
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

Review 9.  Review on Toll-Like Receptor Activation in Myasthenia Gravis: Application to the Development of New Experimental Models.

Authors:  Marieke Robinet; Solène Maillard; Mélanie A Cron; Sonia Berrih-Aknin; Rozen Le Panse
Journal:  Clin Rev Allergy Immunol       Date:  2017-02       Impact factor: 8.667

10.  IDO2 Modulates T Cell-Dependent Autoimmune Responses through a B Cell-Intrinsic Mechanism.

Authors:  Lauren M F Merlo; James B DuHadaway; Samantha Grabler; George C Prendergast; Alexander J Muller; Laura Mandik-Nayak
Journal:  J Immunol       Date:  2016-04-25       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.